Genomic Technology Articles & Analysis
58 news found
This comprehensive approach is particularly valuable in the exploration of novel biomarkers and the elucidation of lncRNA-mediated regulatory networks, which often involve intricate interplays between lncRNAs and their protein-coding counterparts. "At CD Genomics, we are committed to empowering our clients with the most advanced genomic ...
With the introduction of NGS technologies, CD Genomics has revolutionized the field by offering a streamlined and cost-effective solution. "The advent of NGS technologies has opened up new possibilities for researchers working with microsatellites," said the senior scientist at CD Genomics. ...
CD Genomics, a trailblazer in genomics and epigenomics research, is proud to announce the launch of MeRIP Sequencing, a cutting-edge technology revolutionizing the analysis of m6A modifications on RNA molecules. ...
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. ...
CD Genomics, a prominent leader in the genomics and transcriptomics arena, proudly unveils its latest innovation, the Degradome Sequencing service. ...
CD Genomics, a leading provider of genomic solutions, has announced a groundbreaking development in genomic research with the introduction of their Full-Length Transcripts Sequencing (Iso-Seq) technology. ...
DNA affinity purification sequencing technology plays a crucial role in genomic research, enabling scientists to study the binding of transcription factors to DNA, investigate chromatin structure, and identify DNA modifications. ...
Church developed the first direct genomic sequencing method, which resulted in the first genome sequence. ...
Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for existing molecules. ...
ByBayer AG
In the role, Tarun will continue to drive excellence in Eagle Genomics’ technology to deliver the capabilities of its AI-augmented knowledge discovery platform, e[datascientist]™, at scale. e[datascientist]™ uses network science to understand the microbiome in such complex ecosystems that exist within soils, plants, animals and humans, including ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date: Thursday, June 9 at 9:00 a.m. ...
CD Genomics is a world-leading genomics services company, innovating in sequencing services for the genomics industry as well as genotyping, library construction, bioinformatics, aptamers, microarrays, health diagnostics, mutagenesis analysis, and more. ...
This strategy is enabled by our proprietary Cas12a chRDNA genome-editing technology that reproducibly achieves high specificity genome editing at multiple ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation ...
The Bioinformatics-analysis division is a new division of CD Genomics that provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis services. ...
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
Presentations will focus on the progression of Sangamo’s pre-clinical programs emerging from its genomic engineering platform. “The data to be presented at ASGCT reflect the diversity and versatility of Sangamo’s genomic engineering platform, which is being deployed across a range of pre-clinical programs,” said Jason Fontenot, Ph.D., ...
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. ...
We continue to view them as a pioneer in the area of genomic medicines and will explore other possible collaboration opportunities as we work together to transition the autologous sickle cell program back to ...